RT Book, Section
A1 Usatine, Richard P.
A1 Sabella, Camille
A1 Smith, Mindy Ann
A1 Mayeaux, E.J.
A1 Chumley, Heidi S.
A1 Appachi, Elumalai
SR Print(0)
ID 1114876064
T1 Papulosquamous Conditions
T2 The Color Atlas of Pediatrics
YR 2015
FD 2015
PB McGraw-Hill Education
PP New York, NY
SN 978-0-07-176701-9
LK accesspediatrics.mhmedical.com/content.aspx?aid=1114876064
RD 2024/04/25
AB References1Foley  P,  Zuo  Y,  Plunkett  A,  Merlin  K,  Marks  R.  The  frequency  of  common  skin  conditions  in  preschool-aged  children  in  Australia:  seborrheic  dermatitis  and  pityriasis  capitis  (cradle  cap).  Arch  Dermatol.  2003;139(3):318–322.12622623[PubMed:  ]2Breunig  Jde  A,  de  Almeida  HL  Jr,  Duquia  RP,  Souza  PR,  Staub  HL.  Scalp  seborrheic  dermatitis:  prevalence  and  associated  factors  in  male  adolescents.  Int  J  Dermatol.  2012;51(1):46–49.22182377[PubMed:  ]3Schechtman  RC,  Midgley  G,  Hay  RJ.  HIV  disease  and  Malassezia  yeasts:  a  quantitative  study  of  patients  presenting  with  seborrhoeic  dermatitis.  Br  J  Dermatol.  1995;133(5):694–698.8555018[PubMed:  ]4Gaitanis  G,  Magiatis  P,  Hantschke  M,  Bassukas  ID,  Velegraki  A.  The  Malassezia  genus  in  skin  and  systemic  diseases.  Clin  Microbiol  Rev.  2012;25(1):106–141.22232373[PubMed:  ]5Naldi  L,  Alfredo  Rebora  A.  Seborrheic  dermatitis.  N  Engl  J  Med.  2009;360;4:387–396.6Hay  RJ.  Malassezia,  dandruff  and  seborrheic  dermatitis:  an  overview.  Br  J  Dermatol.  2011;165  (2):2–8.21919896[PubMed:  ]7Danby  FW,  Maddin  WS,  Margesson  LJ,  Rosenthal  D.A  randomized,  double-blind,  placebo-controlled  trial  of  ketoconazole  2%  shampoo  versus  selenium  sulfide  2.5%  shampoo  in  the  treatment  of  moderate  to  severe  dandruff.  J  Am  Acad  Dermatol.  1993;29:1008–1012.8245236[PubMed:  ]8Pierard-Franchimont  C.  A  multicenter  randomized  trial  of  ketoconazole  2%  and  zinc  pyrithione  1%  shampoos  in  severe  dandruff  and  seborrheic  dermatitis.  Skin  Pharmacol  Appl  Skin  Physiol.  2002;15(6):434–441.12476017[PubMed:  ]9Aly  R.  Ciclopirox  gel  for  seborrheic  dermatitis  of  the  scalp.  Int  J  Dermatol.  2003;42(1):19–22.12895183[PubMed:  ]10Lebwohl  M,  Plott  T.  Safety  and  efficacy  of  ciclopirox  1%  shampoo  for  the  treatment  of  seborrheic  dermatitis  of  the  scalp  in  the  US  population:  results  of  a  double-blind,  vehicle-controlled  trial.  Int  J  Dermatol.  2004;43(1):17–20.15271196[PubMed:  ]11Chosidow  O,  Maurette  C,  Dupuy  P.  Randomized,  open-labeled,  non-inferiority  study  between  ciclopiroxolamine  1%  cream  and  ketoconazole  2%  foaming  gel  in  mild  to  moderate  facial  seborrheic  dermatitis.  Dermatology.  2003;206:233–240.12673081[PubMed:  ]12Pierard  GE,  Pierard-Franchimont  C,  Van  CJ,  Rurangirwa  A,  Hoppenbrouwers  ML,  Schrooten  P.  Ketoconazole  2%  emulsion  in  the  treatment  of  seborrheic  dermatitis.  Int  J  Dermatol.  1991;30:806–809.1836780[PubMed:  ]13Katsambas  A,  Antoniou  C,  Frangouli  E,  Avgerinou  G,  Michailidis  D,  Stratigos  J.  A  double-blind  trial  of  treatment  of  seborrheic  dermatitis  with  2%  ketoconazole  cream  compared  with  1%  hydrocortisone  cream.  Br  J  Dermatol.  1989;121:353–357.2529893[PubMed:  ]14Dupuy  P,  Maurette  C,  Amoric  JC,  Chosidow  O.  Randomized,  placebo-controlled,  double-blind  study  on  clinical  efficacy  of  ciclopiroxolamine  1%  cream  in  facial  seborrheic  dermatitis.  Br  J  Dermatol.  2001;135:1033–1037.15Vena  GA,  Micali  G,  Santoianni  P,  Cassano  N,  Peruzzi  E.  Oral  terbinafine  in  the  treatment  of  multi-site  seborrheic  dermatitis:  a  multicenter,  double-blind  placebo-controlled  study.  Int  J  Immunopathol  Pharmacol.  2005;18:745–753.16388724[PubMed:  ]16Scaparro  E,  Quadri  G,  Virno  G,  Orifici  C,  Milani  M.  Evaluation  of  the  efficacy  and  tolerability  of  oral  terbinafine  (Daskil)  in  patients  with  seborrheic  dermatitis.  A  multicentre,  randomized,  investigator-blinded,  placebo-controlled  trial.  Br  J  Dermatol.  2001;135(4):854–857.17Firooz  A,  Solhpour  A,  Gorouhi  F,  et  al.  Pimecrolimus  cream,  1%,  vs  hydrocortisone  acetate  cream,  1%,  in  the  treatment  of  facial  seborrheic  dermatitis:  a  randomized,  investigator-blind,  clinical  trial.  Arch  Dermatol.  2006;142:1066–1067.16924062[PubMed:  ]18Freeman  SH.  Efficacy,  cutaneous  tolerance  and  cosmetic  acceptability  of  desonide  0.05%  lotion  (Desowen)  versus  vehicle  in  the  short-term  treatment  of  facial  atopic  or  seborrheic  dermatitis.  Australas  J  Dermatol.  2002;43(3):186–189.12121395[PubMed:  ]19Rigopoulos  D,  Ioannides  D,  Kalogeromitros  D,  Gregoriou  S,  Katsambas  A.  Pimecrolimus  cream  1%  vs.  betamethasone  17-valerate  0.1%  cream  in  the  treatment  of  seborrheic  dermatitis.  A  randomized  open-label  clinical  trial.  Br  ...